Vivos Therapeutics, Inc. (VVOS) focuses on providing innovative, non-invasive treatments for sleep apnea and related health conditions. The company’s flagship product, the Vivos System, is a suite of oral appliances designed to help patients achieve better airflow and breathing patterns, reducing the impact of obstructive sleep apnea. Unlike traditional methods like CPAP machines, Vivos offers a more patient-friendly, wearable alternative that addresses the root causes of airway obstruction.
A key driver of Vivos Therapeutics’ growth is the increasing awareness of sleep apnea’s role in various chronic health conditions, including cardiovascular issues and diabetes. The company’s approach combines medical expertise with dental innovation, targeting a large and growing market of undiagnosed sleep apnea patients. By partnering with dental and healthcare professionals, Vivos builds a network of providers who use its devices to treat patients while also educating them about the benefits of proactive sleep health management.
The company is also leveraging advancements in telehealth and AI-driven diagnostics to reach a broader audience. Its emphasis on research and clinical outcomes further strengthens its credibility among medical professionals and patients. As the demand for more convenient and effective solutions for sleep apnea grows, Vivos is well-positioned to capitalize on its technology and market strategy.
Learn more about Vivos Therapeutics on their official website.
